Equities
Health CareMedical Equipment and Services
  • Price (USD)76.87
  • Today's Change0.63 / 0.83%
  • Shares traded249.56k
  • 1 Year change-8.63%
  • Beta0.4050
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Haemonetics Corporation is a global healthcare company. The Company is engaged in providing a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. The Company’s technology addresses various medical markets, including blood and plasma component collection, the surgical suite, and hospital transfusion services. The Company’s Plasma segment includes plasma collection devices and disposables, donor management software and supporting software solutions sold to plasma customers. Its Blood Center segment manufactures and provides customers with its full line of apheresis solutions for automated blood collection. The Company’s Hospital segment consists of Interventional Technologies, which includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection products, and Blood Management Technologies, which includes Hemostasis Management, Cell Salvage and Transfusion Management products.

  • Revenue in USD (TTM)1.36bn
  • Net income in USD167.68m
  • Incorporated1985
  • Employees3.02k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
UFP Technologies Inc547.56m63.47m1.92bn4.15k30.635.3324.123.518.158.1570.3146.801.044.757.06132,069.5012.0910.1213.8311.5328.9927.0711.5910.641.458.860.33640.0026.0820.5231.2924.4610.82--
Novocure Ltd621.71m-164.19m1.97bn1.49k--5.45--3.18-1.51-1.515.723.250.52463.478.31417,816.50-13.85-9.61-22.39-11.8477.1677.57-26.41-19.321.41--0.6446--18.8211.4918.55--32.52--
Quidelortho Corp2.76bn-358.70m2.04bn6.60k--0.679923.490.7385-5.33-5.3341.0544.400.422.568.74418,893.90-5.450.0044-6.330.00546.9459.13-12.970.0090.66370.5350.45480.00-7.1739.07-20,216.83--48.27--
LivaNova PLC1.28bn-222.15m2.52bn2.90k--2.43--1.97-4.09-4.0923.3718.970.50832.556.20439,786.20-8.85-4.14-11.25-5.0369.3367.61-17.42-9.041.37--0.3781--8.662.94260.39--10.98--
Warby Parker Inc795.09m-14.24m2.70bn2.22k--7.6381.323.40-0.1188-0.11886.532.921.256.77602.34358,473.40-2.23-16.02-2.75-21.0055.2656.59-1.79-13.262.30--0.00--15.1615.8067.74--14.43--
Procept Biorobotics Corp249.12m-90.19m3.20bn756.00--8.23--12.86-1.70-1.704.697.040.55221.793.68329,525.10-19.99-26.94-22.23-29.8162.7154.37-36.20-83.147.75--0.1169--64.84105.2113.68---10.34--
DENTSPLY SIRONA Inc3.72bn-908.00m3.32bn14.00k--1.65--0.8933-4.54-4.5418.4810.090.56462.925.90265,642.80-13.79-4.06-18.07-4.8351.8453.14-24.42-8.590.76196.780.5374---4.34-1.17-589.39--7.9111.28
ICU Medical Inc2.42bn-93.69m3.33bn15.00k--1.6827.551.38-3.83-3.8398.9280.760.57132.4515.31161,339.50-2.21-0.2042-2.51-0.230635.1133.82-3.87-0.33261.521.220.4365--5.4413.47-296.86---3.18--
Envista Holdings Corp2.50bn-1.12bn3.46bn12.30k--1.15--1.38-6.53-6.5314.4917.700.41654.286.21203,569.10-18.70-2.08-21.69-2.5354.7756.91-44.90-5.581.823.400.3174---2.181.90-1,016.37---15.36--
Haemonetics Corp1.36bn167.68m3.69bn3.02k23.184.5213.042.713.323.3226.8217.020.58571.766.65450,156.807.225.418.906.5555.8753.2012.329.180.985726.250.59870.003.956.6042.6416.994.37--
Inspire Medical Systems Inc840.11m66.51m3.79bn1.25k58.925.9650.294.512.182.1827.5821.571.191.7310.19674,246.409.39-4.8310.38-5.4384.6584.597.92-5.127.44--0.00--28.4957.80352.96--70.20--
Integer Holdings Corp1.75bn78.00m4.22bn11.00k56.912.6321.992.422.132.1049.3346.050.54454.874.94158,744.702.433.282.603.5427.1026.704.476.382.144.300.43960.0010.356.4135.805.8216.99--
TransMedics Group Inc488.23m48.95m4.37bn728.0099.2316.4161.858.951.301.3013.377.870.62544.314.36670,641.506.27-5.736.73-6.2859.4762.3710.03-11.868.3221.390.657--82.7479.64241.70--279.42--
Irhythm Technologies Inc618.59m-98.32m4.55bn2.00k--52.47--7.35-3.14-3.1419.742.720.673912.977.26309,293.50-10.71-20.12-12.08-24.3769.3968.61-15.89-23.905.58--0.8819--20.1322.508.20--19.06--
Teleflex Inc3.01bn149.53m5.30bn14.10k37.761.3112.451.763.183.1764.5091.670.41122.106.59213,485.402.044.582.235.0155.6854.774.9711.381.327.590.317819.742.453.26-80.38-31.404.250.00
Data as of Jul 03 2025. Currency figures normalised to Haemonetics Corp's reporting currency: US Dollar USD

Institutional shareholders

53.53%Per cent of shares held by top holders
HolderShares% Held
BlackRock Fund Advisorsas of 31 Mar 20255.67m11.28%
The Vanguard Group, Inc.as of 31 Mar 20254.98m9.91%
Neuberger Berman Investment Advisers LLCas of 31 Mar 20254.35m8.66%
Wellington Management Co. LLPas of 31 Mar 20252.43m4.84%
T. Rowe Price Investment Management, Inc.as of 31 Mar 20252.20m4.37%
SSgA Funds Management, Inc.as of 31 Mar 20251.92m3.82%
Capital Research & Management Co. (Global Investors)as of 31 Mar 20251.58m3.14%
River Road Asset Management LLCas of 31 Mar 20251.40m2.78%
Geode Capital Management LLCas of 31 Mar 20251.22m2.43%
Royce & Associates LPas of 31 Mar 20251.16m2.31%
More ▼
Data from 31 Mar 2025 - 31 Mar 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.